Replies to post #2373 on Skye Bioscience Inc (SKYE)

[cjarmstrong]

I just looked at an old presentation from June 2015 and noticed that Nemus explicitly mentioned that the line chart was a comparison between Marinol and a DHS suppository (dronabinol hemisuccinate) that they didn't license. Now they're using the exact same chart (page 22 of latest presentation) but calling it a comparison between dronabinol (which is fine) and their prodrug THC-VHS. You don't think that's strange? They're giving us data on a old prodrug that no longer has patent protection. If they've made improvements, they definitely aren't communicating it at all.

[Jdanger 2]

Researchers copy and paste 10-20 year old data and re-present it all the time.